Cantabio Announces Publication of Novel Study Demonstrating the Importance of the DJ-1 Protein in the Onset and Pathology of Alzheimer's and Parkinson's disease November 13, 2019
Cantabio Pharmaceuticals and Luxembourg Institute of Health Collaborate to Research the Therapeutic targeting of the DJ-1 Protein to Treat Immune Associated Diseases October 21, 2019
Cantabio Pharmaceuticals to Present Latest Positive In Vivo Results From its DJ-1 Targeting Small Molecule Drug Development Program for Parkinson’s Disease at the Milner Therapeutics Symposium at the University of Cambridge, UK October 1, 2018
Cantabio Pharmaceuticals to Present Positive in vivo Efficacy Results in a Mice Model of Parkinson’s disease of One of Its Orally Administered Novel DJ-1 Protein Targeting Therapeutic Candidates at the XXV International Symposium on Medicinal Chemistry in Ljubljana, Slovenia July 31, 2018
Cantabio Announces Publication of Study on Druggability of the Tau protein in ACS Chemical Neuroscience June 28, 2018
Cantabio Pharmaceuticals to Present Positive in vivo Efficacy Data in a Mice Model of Parkinson’s disease from Its DJ-1 Protein Targeting Therapeutic Program at the Neuro4D Conference in Mainz, Germany May 9, 2018
Cantabio Pharmaceuticals to Present Results from its Tau Protein Targeting Therapeutic Program for the treatment of Alzheimer's Disease at the Advances in Alzheimer's and Parkinson's Therapies, An AAT-AD/PD Focus Meeting in Torino, Italy February 26, 2018
Cantabio Pharmaceuticals to Present Update from Its DJ-1 Protein Targeting Therapeutic Program for the Treatment of Parkinson's Disease at Advances in Alzheimer's and Parkinson's Therapies, An AAT-AD/PD Focus Meeting in Torino, Italy January 22, 2018
Cantabio Pharmaceuticals to Present at 2017 Silicon Valley Bank Healthcare Capital and Connections Summit in Shanghai September 13, 2017
Cantabio announces publication of study on a mechanism by which the DJ-1 protein loses its defensive function in neurodegenerative disease conditions September 11, 2017
